Hormone replacement therapy and endometrial cancer in Ontario, Canada

Meera G. Jain, Thomas E. Rohan, Geoffrey R. Howe

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Estrogen therapy reduces the risk of osteoporosis and cardiovascular diseases but is associated with an increased risk of endometrial cancer. We have assessed the impact of a regimen of estrogen with progestogen on risk of endometrial cancer for women 48 years and older. We conducted a case-control study in Ontario, Canada, from 1994 to 1998 by interviewing registry-based cases (n = 512) and population controls (n = 513) to obtain information on use of hormones and dietary habits. Compared to non-users, the use of opposed hormone therapy in sequential regimen for more than three years showed a borderline increase in risk (OR = 1.49, 95% CI 0.93-2.40), but this increase was much less than among women on unopposed estrogen (OR = 4.12, 95% CI 2.21-7.71). Stronger associations were observed when duration of sequential hormone use was examined as a continuous variable (OR per three years of use = 1.21, 95% CI 1.03-1.42). The effect of opposed hormone therapy on endometrial cancer risk appears to vary both by usage patterns and by patient characteristics of body weight and history of diabetes. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)385-391
Number of pages7
JournalJournal of Clinical Epidemiology
Volume53
Issue number4
DOIs
StatePublished - Apr 2000
Externally publishedYes

Fingerprint

Hormone Replacement Therapy
Ontario
Endometrial Neoplasms
Canada
Hormones
Estrogens
Population Control
Feeding Behavior
Progestins
Osteoporosis
Registries
Case-Control Studies
Cardiovascular Diseases
Therapeutics
Body Weight

Keywords

  • Diabetes
  • Endometrial cancer
  • Estrogens
  • Hormone replacement therapy
  • Obesity
  • Progestogens

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

Hormone replacement therapy and endometrial cancer in Ontario, Canada. / Jain, Meera G.; Rohan, Thomas E.; Howe, Geoffrey R.

In: Journal of Clinical Epidemiology, Vol. 53, No. 4, 04.2000, p. 385-391.

Research output: Contribution to journalArticle

Jain, Meera G. ; Rohan, Thomas E. ; Howe, Geoffrey R. / Hormone replacement therapy and endometrial cancer in Ontario, Canada. In: Journal of Clinical Epidemiology. 2000 ; Vol. 53, No. 4. pp. 385-391.
@article{836daef62d36492eb5d05e9fd488e9d2,
title = "Hormone replacement therapy and endometrial cancer in Ontario, Canada",
abstract = "Estrogen therapy reduces the risk of osteoporosis and cardiovascular diseases but is associated with an increased risk of endometrial cancer. We have assessed the impact of a regimen of estrogen with progestogen on risk of endometrial cancer for women 48 years and older. We conducted a case-control study in Ontario, Canada, from 1994 to 1998 by interviewing registry-based cases (n = 512) and population controls (n = 513) to obtain information on use of hormones and dietary habits. Compared to non-users, the use of opposed hormone therapy in sequential regimen for more than three years showed a borderline increase in risk (OR = 1.49, 95{\%} CI 0.93-2.40), but this increase was much less than among women on unopposed estrogen (OR = 4.12, 95{\%} CI 2.21-7.71). Stronger associations were observed when duration of sequential hormone use was examined as a continuous variable (OR per three years of use = 1.21, 95{\%} CI 1.03-1.42). The effect of opposed hormone therapy on endometrial cancer risk appears to vary both by usage patterns and by patient characteristics of body weight and history of diabetes. Copyright (C) 2000 Elsevier Science Inc.",
keywords = "Diabetes, Endometrial cancer, Estrogens, Hormone replacement therapy, Obesity, Progestogens",
author = "Jain, {Meera G.} and Rohan, {Thomas E.} and Howe, {Geoffrey R.}",
year = "2000",
month = "4",
doi = "10.1016/S0895-4356(99)00192-4",
language = "English (US)",
volume = "53",
pages = "385--391",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Hormone replacement therapy and endometrial cancer in Ontario, Canada

AU - Jain, Meera G.

AU - Rohan, Thomas E.

AU - Howe, Geoffrey R.

PY - 2000/4

Y1 - 2000/4

N2 - Estrogen therapy reduces the risk of osteoporosis and cardiovascular diseases but is associated with an increased risk of endometrial cancer. We have assessed the impact of a regimen of estrogen with progestogen on risk of endometrial cancer for women 48 years and older. We conducted a case-control study in Ontario, Canada, from 1994 to 1998 by interviewing registry-based cases (n = 512) and population controls (n = 513) to obtain information on use of hormones and dietary habits. Compared to non-users, the use of opposed hormone therapy in sequential regimen for more than three years showed a borderline increase in risk (OR = 1.49, 95% CI 0.93-2.40), but this increase was much less than among women on unopposed estrogen (OR = 4.12, 95% CI 2.21-7.71). Stronger associations were observed when duration of sequential hormone use was examined as a continuous variable (OR per three years of use = 1.21, 95% CI 1.03-1.42). The effect of opposed hormone therapy on endometrial cancer risk appears to vary both by usage patterns and by patient characteristics of body weight and history of diabetes. Copyright (C) 2000 Elsevier Science Inc.

AB - Estrogen therapy reduces the risk of osteoporosis and cardiovascular diseases but is associated with an increased risk of endometrial cancer. We have assessed the impact of a regimen of estrogen with progestogen on risk of endometrial cancer for women 48 years and older. We conducted a case-control study in Ontario, Canada, from 1994 to 1998 by interviewing registry-based cases (n = 512) and population controls (n = 513) to obtain information on use of hormones and dietary habits. Compared to non-users, the use of opposed hormone therapy in sequential regimen for more than three years showed a borderline increase in risk (OR = 1.49, 95% CI 0.93-2.40), but this increase was much less than among women on unopposed estrogen (OR = 4.12, 95% CI 2.21-7.71). Stronger associations were observed when duration of sequential hormone use was examined as a continuous variable (OR per three years of use = 1.21, 95% CI 1.03-1.42). The effect of opposed hormone therapy on endometrial cancer risk appears to vary both by usage patterns and by patient characteristics of body weight and history of diabetes. Copyright (C) 2000 Elsevier Science Inc.

KW - Diabetes

KW - Endometrial cancer

KW - Estrogens

KW - Hormone replacement therapy

KW - Obesity

KW - Progestogens

UR - http://www.scopus.com/inward/record.url?scp=0033997276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033997276&partnerID=8YFLogxK

U2 - 10.1016/S0895-4356(99)00192-4

DO - 10.1016/S0895-4356(99)00192-4

M3 - Article

C2 - 10785569

AN - SCOPUS:0033997276

VL - 53

SP - 385

EP - 391

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

IS - 4

ER -